Published in Br J Pharmacol on January 01, 1999
Differential expression of a cutaneous corticotropin-releasing hormone system. Endocrinology (2003) 1.46
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature (1994) 5.12
Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature (1998) 4.65
Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 4.24
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Evidence that nitric oxide does not mediate the hyperpolarization and relaxation to acetylcholine in the rat small mesenteric artery. Br J Pharmacol (1992) 2.80
The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol (1993) 2.64
cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17
Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron (1993) 2.10
CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology (1995) 1.73
Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol (1995) 1.67
Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology (1982) 1.58
Block of calcium-activated potassium channels in mammalian arterial myocytes by tetraethylammonium ions. Am J Physiol (1991) 1.58
A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A (1995) 1.58
Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Science (1982) 1.51
Beta-adrenoceptor agonist mediated relaxation of rat isolated resistance arteries: a role for the endothelium and nitric oxide. Br J Pharmacol (1993) 1.51
Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol (1987) 1.39
Evidence that acetylcholine-mediated hyperpolarization of the rat small mesenteric artery does not involve the K+ channel opened by cromakalim. Br J Pharmacol (1991) 1.36
Regional haemodynamic effects of depressor neuropeptides in conscious, unrestrained, Long Evans and Brattleboro rats. Br J Pharmacol (1988) 1.32
Steady shear and step changes in shear stimulate endothelium via independent mechanisms--superposition of transient and sustained nitric oxide production. Biochem Biophys Res Commun (1996) 1.12
Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol (1997) 1.09
Isolation and amino acid composition of sauvagine. An active polypeptide from methanol extracts of the skin of the South American frog Phyllomedusa sauvagei. Int J Pept Protein Res (1980) 1.06
Heterogeneous populations of K+ channels mediate EDRF release to flow but not agonists in rabbit aorta. Am J Physiol (1994) 1.03
Characterization of the genomic corticotropin-releasing factor (CRF) gene from Xenopus laevis: two members of the CRF family exist in amphibians. Mol Endocrinol (1992) 0.97
Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol (1995) 0.95
Effects of corticotropin-releasing factor on isolated rat heart activity. Am J Physiol (1993) 0.94
Comparison of the biologic actions of corticotropin-releasing factor and sauvagine. Regul Pept (1982) 0.93
Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke (1993) 0.93
The relative importance of nitric oxide and nitric oxide-independent mechanisms in acetylcholine-evoked dilatation of the rat mesenteric bed. Br J Pharmacol (1994) 0.92
Gastrointestinal motor effects of corticotropin-releasing factor in mice. Regul Pept (1990) 0.90
Amunine (ovine CRF), urotensin I and sauvagine, three structurally-related peptides, produce selective dilation of the mesenteric circulation. Pharmacology (1982) 0.90
Contribution of calcium-activated potassium channels to the vasodilator effect of bradykinin in the isolated, perfused kidney of the rat. Br J Pharmacol (1996) 0.89
Corticotropin-releasing factor, sauvagine, and urotensin I: effects on blood flow. Am J Physiol (1985) 0.88
Modulation of nitric oxide-dependent relaxation of pig tracheal smooth muscle by inhibitors of guanylyl cyclase and calcium activated potassium channels. Life Sci (1995) 0.87
Relaxing actions of corticotropin-releasing factor on rat resistance arteries. Br J Pharmacol (1993) 0.87
The relaxation responses to corticotropin-releasing factor in rat aorta are endothelium dependent and gestationally regulated. Am J Obstet Gynecol (1997) 0.87
Attenuation of corticotropin releasing factor-induced hypotension in anesthetized rats with the CRF antagonist, alpha-helical CRF9-41; comparison with effect on ACTH release. Peptides (1992) 0.86
Binding of [125I]Tyr-corticotropin-releasing factor to rabbit aorta is reduced by removal of the endothelium. Eur J Pharmacol (1987) 0.85
Hemodynamic effects of corticotropin releasing hormone in the anesthetized cynomolgus monkey. Peptides (1986) 0.83
Corticotropin-releasing hormone (CRH) receptors in the mesenteric small arteries of rats resemble the (2)-subtype. Biochem Pharmacol (1996) 0.82
Urotensin I effects on intracellular content of cyclic AMP in the rat tail artery. Eur J Pharmacol (1979) 0.78
Effects and pharmacokinetic properties of the rat/human corticotropin-releasing factor in rhesus monkeys. Endocrinology (1985) 0.78
Pharmacological observations on the hypotensive action of extracts of teleost fish Urophyses (urotensin I) in the rat. Br J Pharmacol (1974) 0.77
Corticotropin-releasing factor (CRF) gene family in the brain of the teleost fish Catostomus commersoni (white sucker): molecular analysis predicts distinct precursors for two CRFs and one urotensin I peptide. Mol Mar Biol Biotechnol (1991) 0.77
Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol (1993) 1.29
Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol (1993) 1.18
Corticotrophin-releasing hormone (CRH)-binding protein interference with CRH antibody binding: implications for direct CRH immunoassay. J Endocrinol (1995) 1.06
Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun (1994) 1.06
Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc Natl Acad Sci U S A (1995) 1.05
The actions of the peptides, neuropeptide Y and peptide YY, on the vascular and capsular smooth muscle of the isolated, blood-perfused spleen of the dog. Br J Pharmacol (1987) 0.99
Effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin Sci (Lond) (2002) 0.97
Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. Br J Pharmacol (1994) 0.96
Isolation of human met-enkephalin and two groups of putative precursors (2K-pro-met-enkephalin) from an adrenal medullary tumour. Biochem Biophys Res Commun (1980) 0.96
Purification and characterization of human neuropeptide Y from adrenal-medullary phaeochromocytoma tissue. Biochem J (1984) 0.94
Simultaneous release of neurotensin, somatostatin, enkephalins and catecholamines from perfused cat adrenal glands. Neuropeptides (1982) 0.93
Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia (2001) 0.93
Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia (2009) 0.92
Ectopic production of methionine enkephalin and beta-endorphin. Br Med J (1980) 0.88
Identification of endothelin 1 and big endothelin 1 in secretory vesicles isolated from bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1995) 0.87
Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol (1993) 0.87
Comparison of the haemodynamic actions of neuropeptide Y, angiotensin II and noradrenaline in anaesthetised cats. Eur J Pharmacol (1986) 0.87
Role of hypothalamic neuropeptide Y and orexigenic peptides in anorexia associated with experimental colitis in the rat. Clin Sci (Lond) (2001) 0.86
Markedly reduced blood pressure responsiveness in endotoxemic rats; reversal by neuropeptide Y. Life Sci (1987) 0.86
Evidence for vesicles that transport endothelin-1 in bovine aortic endothelial cells. J Cardiovasc Pharmacol (1993) 0.86
ACTH LPH and related peptides in the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1980) 0.85
Large-molecular-weight somatostatin in human adrenal medullary tissue. Biosci Rep (1982) 0.85
High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. J Intern Med (2011) 0.84
A molecular model for human Big-Endothelin-1 (Big ET-1). FEBS Lett (1996) 0.83
Is endothelin-1 the regulator of myofibroblast contraction during wound healing? Lab Invest (1992) 0.83
Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol (1994) 0.83
Stress-induced changes of circulating neuropeptide Y in the rat: comparison with catecholamines. Regul Pept (1987) 0.83
Responses of the rat pituitary-adrenal axis to hypotensive infusions of corticotropin-releasing factor, vasoactive intestinal peptide and other depressor agents. Regul Pept (1991) 0.81
Characterization of the somatostatin-like immunoreactivity extracted from an adrenal medullary tumour. Biosci Rep (1982) 0.81
A physiological role for neuropeptide Y in regulating the estrogen/progesterone induced luteinizing hormone surge in ovariectomized rats. Neuroendocrinology (1989) 0.81
A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia (1998) 0.81
Cardiovascular effects of neuropeptide Y. Am J Hypertens (1988) 0.81
Involvement of neuropeptide Y in neuroendocrine stress responses. Central and peripheral studies. J Neural Transm Suppl (1990) 0.81
Endothelin receptor antagonists: actions and rationale for their development. Biochem Pharmacol (1994) 0.80
A tissue culture model of the hypophysiotrophic CRF producing neuronal system. Neuroendocrinology (1993) 0.79
Age-related changes in cortico-releasing factor, somatostatin, neuropeptide Y, methionine enkephalin and beta-endorphin in specific rat brain areas. Brain Res (1992) 0.79
Lack of effect of ET antibody or SB 209670 on endotoxin-induced renal failure. J Cardiovasc Pharmacol (1995) 0.78
The effects of chronic glucocorticoid excess, adrenalectomy and stress on neuropeptide Y in individual rat hypothalamic nuclei. Neuropeptides (1993) 0.78
Effect of an antisense oligodeoxynucleotide to endothelin-converting enzyme-1c (ECE-1c) on ECE-1c mRNA, ECE-1 protein and endothelin-1 synthesis in bovine pulmonary artery smooth muscle cells. Mol Pharmacol (2001) 0.78
Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. Br J Pharmacol (1995) 0.77
Heterogeneous receptors mediate endothelin-1-induced changes in blood pressure, hematocrit, and platelet aggregation. J Cardiovasc Pharmacol (1993) 0.77
Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers. J Clin Endocrinol Metab (1991) 0.77
Endothelin-2 synthesis is stimulated by the type-1 tumour necrosis factor receptor and cAMP: comparison with endothelin-converting enzyme-1 expression. J Mol Endocrinol (2000) 0.77
Vasoconstriction in the rat kidney induced by endothelin-1 is blocked by PD 145065. J Cardiovasc Pharmacol (1993) 0.77
Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines. J Cardiovasc Pharmacol (1995) 0.76
The p55 tumor necrosis factor receptor (CD120a) induces endothelin-1 synthesis in endothelial and epithelial cells. Eur J Pharmacol (2000) 0.76
Antagonism of renal and systemic responses to endothelin-1 infusion with PD 145065. Eur J Pharmacol (1994) 0.76
Comparison of the regulation of endothelin-2 and endothelin-converting enzyme-1 b [correction of beta] by forskolin and TNF-alpha in ACHN cells. J Cardiovasc Pharmacol (1998) 0.76
An immunoradiometric assay for the measurement of neuropeptide Y in plasma. Peptides (1986) 0.76
Pro-opiocortin peptides in rat cerebrospinal fluid. Regul Pept (1985) 0.76
CRF immunoreactive peptides in the human hypophysis: a cautionary note. Peptides (1985) 0.75
Regional distribution of pro-opiomelanocortin-derived peptides in the human brain. Neuroendocrinology (1984) 0.75
Contractile activity of endothelin precursors in the isolated gallbladder of the guinea-pig: presence of an endothelin-converting enzyme. Br J Pharmacol (1995) 0.75
Adrenomedullin acts via stimulation of cyclic AMP and not via calcium signalling in vascular cells in culture. J Hum Hypertens (1996) 0.75
Met-enkephalin and related peptides in man. Adv Biochem Psychopharmacol (1982) 0.75
Influence of sodium intake on circulating levels of neuropeptide Y. Life Sci (1987) 0.75
Adrenomedullin acts as a local mediator of vascular homeostasis through interactions which lead to reduced endothelin-1 synthesis and secretion. J Hum Hypertens (1997) 0.75
Stimulation of growth hormone release in man by the potent D2-dopamine agonist CV 205-502: comparison of responses to intravenous and oral administration. J Clin Endocrinol Metab (1990) 0.75
Neuropeptide Y in multiple endocrine neoplasia: release during surgery for phaeochromocytoma. Clin Endocrinol (Oxf) (1987) 0.75
Demonstration of a neuropeptide Y-like immunoreactivity in human phaeochromocytoma extracts. Regul Pept (1984) 0.75
Stability of pro-opiocortin-related peptides in post-mortem mouse brain tissue. Neuroendocrinology (1982) 0.75
Effects of glucocorticoid treatment and acute passive immunization with growth hormone-releasing hormone and somatostatin antibodies on endogenous and stimulated growth hormone secretion in the male rat. J Endocrinol (1991) 0.75
Plasma levels of neuropeptide tyrosine Y (NPY) are increased in human sepsis but are unchanged during canine endotoxin shock despite raised catecholamine concentrations. J Endocrinol (1988) 0.75
Hydatidiform mole: a case with coexistent fetus. J Kans Med Soc (1978) 0.75
Cloning of bovine preproadrenomedullin and inhibition of its basal expression in vascular endothelial cells by staurosporine. Life Sci (1998) 0.75
Circular dichroism studies of human big-endothelin-1 (Big ET-1). J Pept Res (1997) 0.75
Chromatographic characterisation of the circulating neuropeptide Y immunoreactivity from patients with phaeochromocytoma. Regul Pept (1985) 0.75
Pro-enkephalin peptides possessing Met-enkephalin-Arg6-Gly7-Leu8-immunoreactivity in rat CSF, striatum and adrenal gland. Peptides (1985) 0.75
Study of the influence of stress and adrenalectomy on central and peripheral neuropeptide Y levels. Comparison with catecholamines. Neuroendocrinology (1989) 0.75
Dexamethasone treatment in man induces changes in 24-hour growth hormone (GH) secretion profile without altering total GH released. J Clin Endocrinol Metab (1991) 0.75